A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 11, 1997, Pages 496-503

  Hoffmann, C ^a   Zschiesche, M ^a   Franke, G ^a   Hoffmann, A ^b   Terhaag, B ^b   Moritz K U ^a   Siegmund, W ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Arzneimittelwerk Dresden GmbH   (Germany)

Author keywords

Autoinduction; Bioequivalence; Carbamazepine; Carbamazepine 10,11 epoxide; Healthy volunteers; Multiple dose; Single dose

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INDUCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ADULT; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; ENZYME INDUCTION; HUMANS; MALE; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0030720879     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Aarts EM 1965 Evidence for the function of D-glucaric acid as an indicator for drug-enhanced metabolism through the glucuronic acid pathway in man. Biochem Pharmacol 14: 359-363
2. APV Guideline 1987 Studies on bioavailability and bioequivalence. Drugs Made in Germany 30: 161-166
3. Blume H, Gundert-Remy U, Möller H 1991 Controlled/Modified Release Products. Recommendation in Support of EC-Guidelines. Wissenschaftliche Verlagsgesellschaft, Stuttgart
4. Bertilsson L, Tomson T 1986 Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokin 11: 177-198
5. Blume H, Mutschler E 1993 Bioäquivalenz - Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel. Anleitung - Methoden - Materialien (Part l/I). Govi, Eschborn
6. CPMP (Committee for Proprietary Medicinal Products) Working Party on the Efficacy of Medicinal Products 1991 Note for guidance: Investigation of bioavailability and bioequivalence.
7. Diletti E, Hauschke D, Steinijans VW 1991 Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29: 1-8
8. Eichelbaum M, Ekbom K, Bertilsson L, Ringberger VA, Rane A 1975 Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 8: 337-341
9. max for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 29: 394-399
10. Hauschke D, Steinijans VW, Diletti E, Schall R, Luus HG, Elze M, Blume H 1994 Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies. Int J Clin Pharmacol Ther 32: 376-378
11. Heinemeyer C, Roots I, Lestau P, Klaiber, H-R, Dennhardt, R 1986 D-glucaric acid excretion in critical care patients - comparison with 6′-hydroxycortisol excretion and serum γ-glutamyltranspeptidase activity and relation to multiple drug therapy. Br J Clin Pharmacol 21: 9-18
12. Jung K, Pergande M 1984 D-glucarate. In: Bergmeyer HU, Bergmeyer J, Graβl M (eds) Methods of Enzymatic Analysis. Verlag Chemie, Weinheim
13. Krämer G, Hopf HC 1987 Carbamazepin in der Neurologie. Thieme, Stuttgart
14. Kudriakova TB, Sirota LA, Rinzova GI, Gorkov VA 1992 Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol 33: 611-615
15. Levy RH, Morelang TA 1984 Clinical pharmacokinetics of sodium valproate, carbamazepine and phenytoin. Schweiz Rundschau Med (Prax) 73: 159-163
16. MacPhee GJA, Brodie MJ 1985 Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism. Postgrad Med J 61: 779-783
17. Marsh CA 1963 Metabolism of D-glucuronolactone in mammalian systems. Identification of D-glucaric acid as a normal constituent of urine. Biochem J 86: 77-86
18. Martin PJ, Martin JV, Goldberg DM 1975 γ-Glutamyl transpeptidase, triglycerides, and enzyme induction. Br Med J 1: 17-18
19. Morselli PL, Bossi L 1982 Carbamazepine - absorption, distribution, and excretion. In: Woodbury DM, Penry JK, Pippenger CE (eds) Antiepileptic Drugs. Raven Press, New York
20. Perry W, Stamp TCB 1984 Urinary D-glucaric acid excretion during rifampicin/isoniazid and anticonvulsant enzyme induction. Clin Pharmacol Ther 35: 710-715
21. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A 1984 A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 18: 401-410
22. Sauter R, Steinijans VW, Diletti E, Böhm A, Schultz HU 1992 Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 30 (Suppl 1): S7-S30
23. Schulz HU, Düsing R, Lührmann B, Frercks HJ 1992 Investigation of the bioequivalence of two carbamazepine sustained-release formulations in healthy subjects. Int J Clin Pharmacol Ther Toxicol 30: 410-414
24. Shah VP, Midha K, Dighe S, McGilveray U, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S 1992 Analytical methods validation: Bioavailability, bioequivalence, and pharmakokinetic studies. Int J Pharm 82: 1-7
25. Sotaniemi EA, Medzihradsky F, Eliasson G 1974 Glucaric acid as an indicator of use of enzyme-inducing drugs. Clin Pharmacol Ther 15: 417-423
26. Steinijans VW, Hauschke D 1993 International harmonization of regulatory bioequivalence requirements. Clin Res Reg Affairs 10: 203-220
27. Steinijans VW, Hauschke D, Jonkman JHG 1992 Controversies in bioequivalence studies. Clin Pharmacokin 22: 247-253
28. Theisohn M, Sigmund M, Demant L, Roth B, Heimann G, Gesenhues K, Krämer G, Besser R 1987 Metabolisierung von Carbamazepin bei einmaliger und wiederholter Gabe. In: Krämer G, Hopf HC (eds) Carbamazepin in der Neurologie. Thieme, Stuttgart, pp 28-43